The global market for Intravenous Injection Immunoglobulin is expected to grow at a significant CAGR during the forecast period (2021-2027). Immunoglobulins (IGs) are glycoproteins generated in the blood plasma in response to foreign antigens. They are quite intricate and act in a very particular way. They are purified from blood after being fractionated for therapeutic and nontherapeutic purposes. Immunoglobulins of various classes, such as IgG, IgA, and IgM, are utilized to treat a variety of immunological and neurological disorders. The use of a mixture of antibodies (immunoglobulins) to treat health conditions such as primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections is known as intravenous immunoglobulin (IVIG) therapy. It can be injected into a muscle, a vein, or beneath the skin, depending on the formulation.

According to the World Health Organization, approximately 50 distinct Primary Immune Deficiencies (PIDs) currently exist, including particular antibody deficiency, X-lined hypo-gamma-globulinemia, and others. There are 176 different kinds of PIDs, which are uncommon genetic diseases. According to the National Library of Medicine and the National Institutes of Health, around 6.0 million people globally suffer from PID. Over the forecast period, rising rates of these illnesses are likely to drive the demand for immunoglobulin treatments.

IVIG treatments are in high demand for the treatment of acquired and primary immunodeficiency disorders since they are the most effective and only therapeutic option available. Furthermore, sedentary lifestyle choices such as the eating of saturated fats, salt, and sweets, as well as a lack of physical activity and excessive alcohol use, have contributed to a rise in the incidence of these illnesses. The rise in the incidence of lifestyle-related illnesses such as obesity and antibody deficiency disorders is expected to drive the growth the market forward.

To expand their share in the global market, the leading companies adopt strategies such as acquisitions, partnerships, and new product releases. For instance, Kedrion Biopharma concluded enrollment for their CARES10 trial in January 2020, which is a Phase 3 multi-center, open-label, prospective research evaluating the pharmacokinetics, safety, and effectiveness of a 10% intravenous immunoglobulin in people with primary immunodeficiency illness.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type – IgG, IgA, IgM, IgE, IgD

o By Application – Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy

o By End – User – Hospitals, Speciality Clinics

    • Competitive Landscape: Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, and BDI Pharma Inc. among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Intravenous Injection Immunoglobulin Market Report 

By Type

    • IgG

    • IgA

    • IgM

    • IgE

    • IgD 

By Application

    • Hypogammaglobulinemia

    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    • Primary Immunodeficiency Diseases

    • Myasthenia Gravis

    • Multifocal Motor Neuropathy

By End – User

    • Hospitals

    • Specialty Clinics

By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa